After Pruning Orchard, Gaspar Focuses on High Value Opportunities

Orchard Therapeutics founder and former chief scientific officer Bobby Gaspar took the helm of the gene therapy company in March to replace CEO Mark Rothera when he stepped down. Since taking over, Gaspar has led a restructuring of the company and narrowed the focus to prioritize what it saw as high-value programs including its gene therapy for metachromatic leukodystrophy, a rare and life-threatening inherited disease of the body’s metabolic system. We spoke to Gaspar about the company’s sharpened focus, its gene therapy in development for metachromatic leukodystrophy, and where he sees the greatest opportunities for Orchard going forward.